Board of Directors

Philippe Boisseau Director, Total S.A.
Philippe Boisseau
Elected 2010

Mr. Boisseau is President, Marketing & Services and a member of the Executive Committee of Total S.A., a French oil and gas company, since January 2012. Previously, Mr. Boisseau served as President of the Gas & Power division of Total from February 2007 to December 2011. He also previously served as a member of Total's Management Committee since January 2005. He served as President, Middle East of Total's Exploration & Production division between 2002 and February 2007 and, before that, as General Manager of Total Austral in Argentina from 1999 to 2002. From 1995 to 1999, he worked in several management positions within the Refining and Marketing division in the U.S. and France. At the beginning of his career, he served in various positions within French government ministries. He graduated from the leading French engineering school Ecole Polytechnique and also has a DEA (master's degree) in particle physics from the Ecole Normale Supérieure.


Recent Stock Transactions by Philippe Boisseau
Date Type Shares Traded Price Range
Dec 24, 2012 Acquisition (Non Open Market) 1,677,852 2.98
Dec 24, 2012 Acquisition (Non Open Market) 1,677,852 2.98
Feb 23, 2012 Buy 2,288,356 5.78
Feb 23, 2012 Buy 2,288,356 5.78
Dec 8, 2010 Statement of Ownership 0 n/a
Sep 30, 2010 Acquisition (Non Open Market) 9,651,004 n/a
Nam-Hai Chua Ph.D. Director, Rockefeller University, Laboratory of Plant Molecular Biology
Nam-Hai Chua Ph.D.
Elected 2012

Professor Nam-Hai Chua is Andrew W. Mellon Professor and Head of the Laboratory of Plant Molecular Biology at the Rockefeller University since 1981. He is a fellow of the Royal Society of the United Kingdom, a Foreign Academician of the China Academy of Sciences and of the Academia Sinica in Taiwan. Professor Chua was a Director of Delta and Pine Land (USA) from 1993 until it was sold to Monsanto in 2007. He was also a director of Arpida Ltd (Munchenstein, Switzerland) from 2004-2008 and served as chairman of its compensation committee from 2006-2008. He has been a director of Temasek Life Sciences Laboratory, Singapore, and chairman of its Strategic Research Program since 2003 and was appointed Deputy Chairman, Management Board of Temasek Life Sciences Laboratory in October 2012. Dr Chua received his Ph.D. from Harvard University.


Recent Stock Transactions by Nam-Hai Chua Ph.D.
Date Type Shares Traded Price Range
Aug 6, 2014 Acquisition (Non Open Market) 3,000 n/a
Aug 1, 2013 Acquisition (Non Open Market) 3,000 n/a
Jul 19, 2012 Acquisition (Non Open Market) 3,000 n/a
John Doerr Director and Chair of the Nominating and Governance Committee, Kleiner Perkins Caufield & Byers
John Doerr
Elected 2006

John Doerr is a Partner at Kleiner Perkins Caufield & Byers, a venture capital firm, since 1980. Mr. Doerr currently serves on the board of directors of Google Inc., as well as on the boards of directors of several private companies. Previously, Mr. Doerr served on the board of directors of Amazon.com, Inc. Mr. Doerr holds Bachelor of Science and Master of Science in Electrical Engineering degrees from Rice University and a Master of Business Administration degree from Harvard University.


Recent Stock Transactions by John Doerr
Date Type Shares Traded Price Range
Aug 6, 2014 Acquisition (Non Open Market) 3,000 n/a
May 15, 2014 Buy 172,186 3.02
Aug 1, 2013 Acquisition (Non Open Market) 3,000 n/a
May 24, 2013 Buy 24,402 2.85
Dec 24, 2012 Buy 1,677,852 2.98
Aug 31, 2012 Buy 270,270 3.70
Jul 19, 2012 Acquisition (Non Open Market) 3,000 n/a
May 18, 2012 Buy 211,864 2.36
Feb 23, 2012 Acquisition (Non Open Market) 865,051 5.78
Jul 19, 2011 Acquisition (Non Open Market) 3,000 n/a
Jun 2, 2011 Acquisition (Non Open Market) 8,503 n/a
Sep 30, 2010 Acquisition (Non Open Market) 3,594,605 n/a
Sep 30, 2010 Acquisition (Non Open Market) 66,297 n/a
Sep 30, 2010 Acquisition (Non Open Market) 3,660,902 n/a
Sep 30, 2010 Acquisition (Non Open Market) 3,800,587 n/a
Sep 27, 2010 Statement of Ownership 0 n/a
Sep 27, 2010 Statement of Ownership 0 n/a
Sep 27, 2010 Statement of Ownership 0 n/a
Sep 27, 2010 Statement of Ownership 0 n/a
Geoffrey Duyk M.D., Ph.D Director , TPG Biotech
Geoffrey Duyk M.D., Ph.D
Elected 2012

Dr. Geoffrey Duyk was a member of the Board from May 2006 through May 2011, and re-joined the Board in May 2012. Dr. Duyk is a partner of TPG Growth, LLC, an affiliate of TPG Biotechnology Partners II, L.P. Previously, he served on the board of directors and was President of Research and Development at Exelixis, Inc., a biopharmaceutical company focusing on drug discovery, from 1996 to 2003. Prior to Exelixis, Dr. Duyk was Vice President of Genomics and one of the founding scientific staff at Millennium Pharmaceuticals, from 1993 to 1996. Before that, Dr. Duyk was an Assistant Professor at Harvard Medical School in the Department of Genetics and Assistant Investigator of the Howard Hughes Medical Institute. Dr. Duyk currently serves on the boards of directors of several private companies and the non-profit Wesleyan University Board of Trustees. He served on the board of directors of Agria Corporation from August 2007 to May 2009, Cardiovascular Systems, Inc. (formerly Replidyne, Inc.) from 2004 to February 2009, Exelixis, Inc. from 1996 to 2003. Dr. Duyk holds a Bachelor of Arts degree in Biology from Wesleyan University and Doctor of Philosophy and Medicine degrees from Case Western Reserve University.


Recent Stock Transactions by Geoffrey Duyk M.D., Ph.D
Date Type Shares Traded Price Range
Aug 6, 2014 Acquisition (Non Open Market) 3,000 n/a
Aug 1, 2013 Acquisition (Non Open Market) 3,000 n/a
Jul 19, 2012 Acquisition (Non Open Market) 3,000 n/a
May 4, 2012 Statement of Ownership 0 n/a
Sep 27, 2010 Statement of Ownership 0 n/a
John Melo President & Chief Executive Officer, Amyris
John Melo
Elected 2007

John Melo has nearly three decades of combined experience as an entrepreneur and thought leader in the global fuels industry and technology innovation. Mr. Melo has served as our Chief Executive Officer and a director since January 2007 and as our President since June 2008. Before joining Amyris, Mr. Melo served in various senior executive positions at BP Plc (formerly British Petroleum), one of the world’s largest energy firms, from 1997 to 2006, most recently as President of U.S. Fuels Operations from 2004 until December 2006, and previously as Chief Information Officer of the refining and marketing segment from 2001 to 2003, Senior Advisor for e-business strategy to Lord Browne, BP Chief Executive, from 2000 to 2001, and Director of Global Brand Development from 1999 to 2000. Before joining BP, Mr. Melo was with Ernst & Young, an accounting firm, from 1996 to 1997, and a member of the management teams of several startup companies, including Computer Aided Services, a management systems integration company, and Alldata Corporation, a provider of automobile repair software to the automotive service industry. Mr. Melo currently serves on the board of directors of U.S. Venture, Inc. and Renmatix, Inc., and also serves as Vice Chairman of the board of directors of BayBio. Mr. Melo was formerly an appointed member to the U.S. section of the U.S.-Brazil CEO Forum. 

Download Photo


Recent Stock Transactions by John Melo
Date Type Shares Traded Price Range
May 15, 2014 Sell 172,186 3.02
May 5, 2014 Acquisition (Non Open Market) 300,000 n/a
Apr 1, 2014 Disposition (Non Open Market) 126,677 4.44
Jan 1, 2014 Disposition (Non Open Market) 3,363 4.71
Jun 3, 2013 Acquisition (Non Open Market) 239,000 n/a
May 24, 2013 Sell 24,402 2.85
Apr 1, 2013 Disposition (Non Open Market) 6,113 3.06
Jan 2, 2013 Disposition (Non Open Market) 3,364 3.20
Aug 31, 2012 Sell 553,730 3.70
Aug 31, 2012 Sell 115,000 3.70
Aug 31, 2012 Option Execute 553,730 0.28
Aug 31, 2012 Option Execute 115,000 0.28
May 15, 2012 Acquisition (Non Open Market) 3,273 1.53
Apr 9, 2012 Acquisition (Non Open Market) 250,000 n/a
Jan 3, 2012 Disposition (Non Open Market) 3,225 12.27
Oct 10, 2011 Automatic Sell 20,000 17.22
Oct 10, 2011 Option Execute 20,000 0.28
Aug 10, 2011 Automatic Sell 27,500 20.02 - 20.67
Aug 10, 2011 Option Execute 27,500 0.28
Aug 9, 2011 Automatic Sell 23,800 19.66 - 20.44
Aug 9, 2011 Option Execute 23,800 0.28
Aug 8, 2011 Automatic Sell 18,500 20.04 - 20.55
Aug 8, 2011 Option Execute 18,500 0.28
Jul 8, 2011 Automatic Sell 6,000 28.28
Jul 8, 2011 Option Execute 6,000 0.28
Jul 7, 2011 Automatic Sell 7,000 27.97
Jul 7, 2011 Option Execute 7,000 0.28
Jul 6, 2011 Automatic Sell 4,500 28.21
Jul 6, 2011 Option Execute 4,500 0.28
Jul 5, 2011 Automatic Sell 8,000 27.89
Jul 5, 2011 Option Execute 8,000 0.28
Jul 1, 2011 Automatic Sell 19,970 28.05
Jul 1, 2011 Option Execute 19,970 0.28
Jun 30, 2011 Automatic Sell 11,900 28.19
Jun 30, 2011 Option Execute 11,900 0.28
Apr 15, 2011 Acquisition (Non Open Market) 23,000 n/a
Mar 29, 2011 Automatic Sell 53,100 27.99
Mar 29, 2011 Option Execute 53,100 0.28
Mar 28, 2011 Automatic Sell 56,000 27.10
Mar 28, 2011 Option Execute 56,000 0.28
Carole Piwnica Director and Chair of the Leadership Development and Compensation Committee, Naxos
Carole Piwnica
Elected 2009

Ms. Piwnica is Director of NAXOS UK, a consulting firm advising private equity, since January 2008. Previously, Ms. Piwnica served as a director, from 1996 to July 2006, and Vice-Chairman of Governmental Affairs, from 2000 to 2006, of Tate & Lyle Plc, a European food and agricultural ingredients company. She was a chairman of Amylum Group, a European food ingredient company and affiliate of Tate & Lyle Plc, from 1996 to 2000. From 1992 to 1996, Ms. Piwnica held general management positions and board memberships in various other European food companies, including Cacao Barry and Vital Sogéviandes. Ms. Piwnica was a member of the board of directors of Aviva plc, a British insurance company, from May 2003 to December 2011, a member of the Biotech Advisory Council of Monsanto from May 2006 to October 2009, a member of the board of directors of Dairy Crest from 2007 until 2010, and a member of the board of directors of Toepfer Gmbh from 1996 until 2010. In 2010, she was appointed as a member of the boards of Eutelsat (satellites, France) and Sanofi (pharmaceuticals, France). Ms. Piwnica holds a Law degree from the Université Libre de Bruxelles and a Master of Laws degree from New York University. She has also been a member of the bar association of the state of New York, USA since 1985.


Recent Stock Transactions by Carole Piwnica
Date Type Shares Traded Price Range
Aug 6, 2014 Acquisition (Non Open Market) 3,000 n/a
Aug 1, 2013 Acquisition (Non Open Market) 3,000 n/a
Jul 19, 2012 Acquisition (Non Open Market) 3,000 n/a
Jul 19, 2011 Acquisition (Non Open Market) 3,000 n/a
Fernando Reinach Ph.D. Director, Pitanga
Fernando Reinach Ph.D.
Elected 2008

Dr. Fernando Reinach is managing partner of Pitanga Fund, a venture capital fund based in Brazil, since May 2011 and serves as a consultant to Votorantim Novos Negócios Ltda., the private equity arm of Votorantim Group, a large Brazilian industrial group, since June 2010. From 2001 to May 2010, Dr. Reinach was a General Partner at Votorantim Novos Negócios Ltda. Before joining Votorantim, he was involved in the creation of two companies, Genomic Engenharia Molecular Ltda., a molecular diagnostic laboratory, and .ComDominio S/A, a datacenter company. Dr. Reinach holds a Bachelor of Science degree in biology from the University of São Paulo and a Doctor of Philosophy degree in Cell and Molecular Biology from Cornell University Medical College.


Recent Stock Transactions by Fernando Reinach Ph.D.
Date Type Shares Traded Price Range
Aug 6, 2014 Acquisition (Non Open Market) 3,000 n/a
Aug 1, 2013 Acquisition (Non Open Market) 3,000 n/a
Dec 24, 2012 Buy 83,892 2.98
Jul 19, 2012 Acquisition (Non Open Market) 3,000 n/a
Feb 23, 2012 Acquisition (Non Open Market) 86,505 5.78
Jul 19, 2011 Acquisition (Non Open Market) 3,000 n/a
HH Sheikh Abdullah bin Khalifa Al Thani Director
HH Sheikh Abdullah bin Khalifa Al Thani
Elected 2012

His Highness Sheikh Abdullah bin Khalifa Al Thani has served as Special Advisor to the Emir since his appointment in April 2007, and was Prime Minister of Qatar from October 1996 to April 2007. His Highness has served as Chairman of the board of directors of Qatar Investment and Projects Development Holding Company, a Qatari investment group, since March 2011 and as Chairman of the board of directors of Specialized International Services (SIS) Qatar, a business investment company, since October 2011. His Highness graduated from the Royal Military Academy Sandhurst.


Recent Stock Transactions by HH Sheikh Abdullah bin Khalifa Al Thani
Date Type Shares Traded Price Range
Aug 6, 2014 Acquisition (Non Open Market) 3,000 n/a
Aug 1, 2013 Acquisition (Non Open Market) 3,000 n/a
Mar 27, 2013 Buy 1,533,742 3.26
Dec 24, 2012 Buy 3,355,704 2.98
Jul 19, 2012 Acquisition (Non Open Market) 3,000 n/a
Mar 15, 2012 Statement of Ownership 0 n/a
Neil Williams Director and Chair of the Audit Committee, Intuit, Inc.
Neil Williams
Elected 2013

R. Neil Williams has served as Intuit's Senior Vice President and Chief Financial Officer since January 2008. He is responsible for all financial aspects of Intuit, including corporate strategy and business development, investor relations, financial operations and real estate. Before joining Intuit, Mr. Williams was the Executive Vice President and Chief Financial Officer for Visa U.S.A., Inc. In that role, he led all financial functions for the company and its subsidiaries, including financial planning, business planning and financial monitoring. Williams concurrently served as Chief Financial Officer for Inovant LLC, Visa's global information technology organization, responsible for global transactions processing and technology development. His previous banking experience includes senior financial positions at commercial banks in the Southern and Midwest regions of the United States. Williams, a certified public accountant, received his Bachelor's degree in business administration from the University of Southern Mississippi.


Patrick Yang Ph.D. Director
Patrick Yang Ph.D.
Elected 2014

Dr. Patrick Y. Yang was appointed to the Board of Amyris, effective July 1, 2014. From January 2010 to March 2013, he served as Head of Global Technical Operations for F. Hoffmann-La Roche Ltd. where he was responsible for the company's pharmaceutical manufacturing, process development, engineering, quality, regulatory, supply chain and procurement. Before joining Roche, he worked for Genentech, Merck & Co., General Electric and Life Systems, during which time he developed significant experience with pharmaceuticals and biotechnology manufacturing, engineering, technology, and supply chain management. Dr. Yang currently serves on the board of directors of Tesoro Corporation, a public independent refining and marketing company, since December 2010; Codexis, a public company that develops biocatalysts for the pharmaceutical and fine chemicals markets, since February 2014; Celladon Corporation, a public clinical-stage gene therapy biotechnology company, since March 2014; and PharmaEssentia Corporation, a clinical-stage biotechnology company, since March 2014; and previously served on the board of TaiMed, Inc., a clinical-stage biotechnology company, in 2007-2009. Dr. Yang earned a Bachelor of Science in Engineering from the National Chiaotung University in Taiwan, a Master of Science in Electrical Engineering from the University of Cincinnati and a Ph.D. in engineering from the Ohio State University.


Stock transaction information provided by EDGAR Online. Amyris makes no representation or warranty with respect to any of the information contained herein, takes no responsibility for supplementing, updating or correcting any such information and shall have no liability with respect to any such information. This listing does not include derivatives, such as stock option grants or shares purchased through an employee stock purchase plan. For recent transactions, including derivative transactions, see our Section 16 SEC filings page.